Posters

      Reduced Exposure To Harmful And Potentially Harmful Constituents After Five Days Of Use Of tobacco Heating System 2.2: A Comparison With Continued Combustible Cigarette Use Or Smoking Abstinence [Japan]

      Haziza, C.; de La Bourdonnaye, G.; Baker, G.; Benzimra, M.; Ancerewicz, J.; Picavet, P.; Miura, H.; Lüdicke, F.

      Conference date
      Feb 28, 2015
      Conference name

      Society for Research on Nicotine and Tobacco (SRNT) 2015
      Link to more information
      Topic
      Summary

      This study is part of a clinical program to assess the Tobacco Heating System 2.2 (THS 2.2), a candidate modified risk tobacco product. The objective of this study was to assess the maximum potential reduction in exposure to selected harmful and potentially harmful constituents (HPHCs) after 5 days of use of THS 2.2 under controlled conditions compared to continued smoking of combustible cigarettes (CC) and smoking abstinence (SA). Biomarker of exposure (BoExp) to fourteen HPHCs were evaluated. This was an open-label, randomized, controlled, 3-arm parallel group, confinement study in 160 healthy smokers aged between 21 and 65 years. Smokers smoked their CC at baseline for 2 days, and were subsequently randomized to continue to smoke CC, to switch to THS 2.2, or to stop smoking for 5 days. Twenty-four hour urine was collected to evaluate the levels of BoExp using validated methods. This study was conducted according to GCP and is registered in ClinicalTrials.gov, number NCT01959932. At the end of exposure, the levels of all evaluable BoExp were significantly reduced by at least 50% in the THS 2.2 arm as compared to CC and approaching results obtained in the SA arm. The reductions in BoExp levels were observed within 24 hours of starting THS 2.2 use. The average daily product use between baseline and the end of exposure slightly increased in the THS 2.2 arm, and remained in the same range in the CC arm. The Nicotine Equivalents were similar in both arms throughout the exposure period. THS 2.2 was well tolerated.THS 2.2 showed a significant reduction in exposure to HPHCs after 5 days of THS 2.2 use, as compared to CC, approaching levels of HPHCs observed after 5 days of smoking abstinence.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.